Retatrutide · lyophilised · lot r30 1250
Reta 30 MGRetatrutide · 30 mg
One vial of freeze-dried retatrutide, sold as a research compound. Not a medicine, not approved anywhere yet, and we are not going to pretend otherwise — what we can tell you is exactly what the independent laboratory found in batch r30 1250, and the report is on this page as it was issued.
Buy now · $150.00 Why it says “research use only”
- Content and purity reported by Janoshik Analytical for batch r30 1250
- Sealed, dry powder · the seller keeps stock sealed, dry and out of light, at ambient
- Research use only · 18 or older · water and syringes in the bundle
The vial
What you actually receive, and what it costs — no basket, no options, one thing done properly.
tested
Research compound · peptide
Reta 30 MG
Retatrutide · 30 mg
$150.00 / bundle, delivery inside it
Lyophilised powder · one vial, rubber closure, aluminium seal · bacteriostatic water and syringes in the price
Retatrutide is a synthetic research peptide that leans on three receptors at once — GLP-1, GIP and glucagon. We buy it as powder, send a sample out for blind analysis, and sell the rest of the batch as what it is: a research chemical in a glass vial.
Delivery is inside that price, not added at the till: FedEx 2-Day delivery, with tracking sent as it ships. Refunds: see §7 — a vial that has left the fridge cannot go back on the shelf.
Our listing saysReta 30mg w/BAC water and syringes. Flat rate of $150 for 30mg Reta, BAC water, and syringes. Shipping will be FedEx 2-Day delivery.Read from the listing the Buy button opens, on 4 November 2026.
- Sent FedEx 2-Day from the US, tracked
- Vial, bacteriostatic water and syringes, one flat price
- The laboratory's report, opened at their page
The report, and the honest edge of it
The laboratory named here — Janoshik Analytical, an independent analytical lab that anyone can commission — issued this certificate for batch r30 1250 as a blind assay: they were not told which GLP-1 peptide they were holding, and had to distinguish it from semaglutide and tirzepatide first. The supplier had that testing done, and we publish the result: the report itself lists the client it was ordered by and the manufacturer code tfc-alice, so we do not claim to have paid for it. It is still the only testing we can show you, it was run by somebody with no reason to flatter us, and a blind identity panel is a stronger result than “we trust our supplier”.
| Laboratory | Janoshik Analytical (janoshik.com) |
|---|---|
| Task number | 202279 |
| Batch / sample | r30 1250 |
| Panel requested | Common GLP-1 peptide blind test (Semaglutide, Tirzepatide and Retatrutide) |
| Identity | Retatrutide — blind panel vs semaglutide / tirzepatide |
| Content | 35.04 mg; 35.42 mg — quantification, two runs |
| Purity | 99.767%; 99.776% — HPLC, two runs |
| Ordered / received | 2026-06-16 / 2026-06-29 |
| Analysis conducted | 2026-07-02 |
| Verification key | T5F1RUTVBUNB |
What the report does not say
A certificate proves the sample that arrived, on the day it was analysed. It is silent on the tests nobody ordered, and we would rather list that gap than let a smart badge imply it away. The full list — sterility, endotoxin, water content, pH, residual solvents, heavy metals, the fill weight of the vial you buy, the facility's classification, a second laboratory — with what each one would have proved, is § Not tested and not claimed on the legal page. Ask us by email and we will send you what we have.
About retatrutide
The published science, briefly — and the regulatory position, plainly.
Retatrutide (development code LY3437973) is a synthetic 39-residue peptide designed as a triple agonist: it activates the GLP-1, GIP and glucagon receptors at once, which is one more pathway than the dual and single agonists that preceded it. The medicinal chemistry — convergent solid-phase synthesis of an acylated 39-mer — is published, so the compound's identity is public science; what a certificate adds is only the evidence that the powder in this vial is that compound at the stated purity.
It is being studied by Eli Lilly in Phase 3 trials across obesity, type 2 diabetes, knee osteoarthritis pain, obstructive sleep apnoea and metabolic liver disease, and in October 2026 the FDA told Lilly it regards retatrutide as a drug rather than a biologic — a dispute now in court. None of that is a claim about your results. It is context for why a shop selling this material sells it for research, and why the honest sentence on this page is not approved, still in trials.
Read it yourself: Lilly's own summary · the FDA on unapproved GLP-1 products · the synthesis paper.
Is this a medicine, or a weight-loss product?
Neither, as far as we are allowed to say. Retatrutide is an investigational compound: as of November 2026 it is approved in no country, Eli Lilly's Phase 3 programme is still running, and a US application is expected in early 2027. We sell it as a research compound, not as a treatment, and we make no claim about what it will do for you.
Why does the page keep saying “research use only”?
Because an unapproved substance cannot lawfully be marketed as a drug in the United States. The FDA has already sent warning letters to shops selling retatrutide and its neighbours under a research-use label — not because of the label itself, but because the rest of the page read like a human product with amounts, schedules and outcomes. So that language lives in published studies, not on our shelf.
Do I get bacteriostatic water and a syringe?
Yes. The listing puts bacteriostatic water and syringes in the flat price, and the Buy button leads to that listing. What we do not give you is a dilution chart or a dose — the procedure is part of the work, and the page deliberately stays out of it.
Where does the material come from?
We buy it from a peptide manufacturer identified on the laboratory's report only as tfc-alice. We publish the laboratory's findings rather than a supply chain story: the report says what the batch is and how pure it is, which is the part you can verify.
The fine print, before you buy
- Sold as a research compound for laboratory use — retatrutide is not approved by the FDA and this is not a medicine.
- The certificate we publish is one batch, tested once by one independent lab; sterility and endotoxin have not been tested, and we say so rather than implying it.
- Bacteriostatic water and syringes ship in the flat price, and refunds are limited because an opened research vial cannot be resold as unopened.
Read all of it — 11 short sections No account, no subscription, no consent banner. Terms last revised 15 November 2026.